Gemini Therapeutics, Inc. GMTX
We take great care to ensure that the data presented and summarized in this overview for Gemini Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding GMTX
View allLatest Institutional Activity in GMTX
Top Purchases
Top Sells
About GMTX
Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Insider Transactions at GMTX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 17
2025
|
Kevin Bitterman |
SELL
Open market or private sale
|
Indirect |
70,000
-1.15%
|
$6,160,000
$88.51 P/Share
|
|
Oct 16
2025
|
Kevin Bitterman |
SELL
Open market or private sale
|
Indirect |
1,425
-0.3%
|
$109,725
$77.11 P/Share
|
|
Oct 15
2025
|
Kevin Bitterman |
SELL
Open market or private sale
|
Indirect |
22,160
-2.22%
|
$1,706,320
$77.46 P/Share
|
|
Oct 08
2025
|
Kevin Bitterman |
SELL
Open market or private sale
|
Indirect |
71,961
-2.64%
|
$5,037,270
$70.4 P/Share
|
|
Oct 07
2025
|
Kevin Bitterman |
SELL
Open market or private sale
|
Indirect |
18,039
-1.54%
|
$1,226,652
$68.51 P/Share
|
|
Sep 09
2025
|
John D Quisel Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+5.5%
|
$10,000
$1.01 P/Share
|
|
Aug 22
2025
|
Kevin Bitterman |
SELL
Open market or private sale
|
Indirect |
2,287
-0.39%
|
$139,507
$61.03 P/Share
|
|
Aug 14
2025
|
Kevin Bitterman |
SELL
Open market or private sale
|
Indirect |
7,212
-1.2%
|
$432,720
$60.99 P/Share
|
|
Aug 13
2025
|
Kevin Bitterman |
SELL
Open market or private sale
|
Indirect |
24,962
-3.99%
|
$1,522,682
$61.15 P/Share
|
|
Aug 05
2025
|
Kevin Bitterman |
SELL
Open market or private sale
|
Indirect |
395
-0.06%
|
$23,700
$60.95 P/Share
|
|
Jul 30
2025
|
Kevin Bitterman |
SELL
Open market or private sale
|
Indirect |
8,492
-1.34%
|
$518,012
$61.04 P/Share
|
|
Jul 24
2025
|
Kevin Bitterman |
SELL
Open market or private sale
|
Indirect |
13,033
-2.01%
|
$795,013
$61.17 P/Share
|
|
Jul 23
2025
|
Kevin Bitterman |
SELL
Open market or private sale
|
Indirect |
29,837
-4.41%
|
$1,790,220
$60.97 P/Share
|
|
Jul 18
2025
|
Kevin Bitterman |
SELL
Open market or private sale
|
Indirect |
664
-0.1%
|
$40,504
$61.13 P/Share
|
|
Jul 17
2025
|
Jean M. Franchi Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,031
-3.1%
|
$119,829
$59.0 P/Share
|
|
Jul 10
2025
|
Jean M. Franchi Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,000
-2.96%
|
$114,000
$57.5 P/Share
|
|
Jul 09
2025
|
John D Quisel Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
34,800
-9.02%
|
$1,914,000
$55.72 P/Share
|
|
Jul 09
2025
|
John D Quisel Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
34,800
+15.04%
|
$313,200
$9.86 P/Share
|
|
Jul 03
2025
|
John D Quisel Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
5,200
-3.11%
|
$286,000
$55.09 P/Share
|
|
Jul 03
2025
|
John D Quisel Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,200
+3.02%
|
$46,800
$9.86 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 222K shares |
|---|---|
| Exercise of conversion of derivative security | 198K shares |
| Open market or private sale | 1.18M shares |
|---|